Session IV - Key Considerations for Demonstrating Utility of Pre-Clinical Models

Focus Questions / Issues

1. Against what should we validate non-clinical assays; QT prolongation in humans, clinical proarrhythmic events or other clinical events, such as all-cause mortality?

2. Can the gap between QT prolongation and proarrhythmic events be addressed in clinical studies (i.e. how can we increase clinical studies’ predictive value for proarrhythmic risk in patients)?

3. How are clinical outcomes data best captured (post market surveillance using ADR data, focused post-market studies, others)?

4. Could a validation program using known proarrhythmic drugs and controls (e.g. the ILSI HESI and QT Prodict initiatives, number of drugs TBD) provide sufficient evidence to demonstrate the predictive value of non-clinical assays (or combination of assays)? From the regulatory and patient safety perspective, how would this program look like?